» Articles » PMID: 31771180

Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells

Overview
Journal Cells
Publisher MDPI
Date 2019 Nov 28
PMID 31771180
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin and insulin-like growth factor-1 (IGF1) have important roles in breast cancer development. The recent identification of nuclear insulin (INSR) and IGF1 (IGF1R) receptors provides a novel paradigm in the area of signal transduction. The fact that INSR and IGF1R can function as transcription factors, capable of binding DNA and controlling transcription, adds a new layer of biological complexity by conferring upon cell-surface receptors the ability to regulate genomic events. The present study was designed to assess the hypothesis that insulin and IGF1 pathways elicit differential effects on subcellular distribution and activation of ERK1/2 and AKT. To this end, MCF7 breast cancer-derived cell lines with specific INSR or IGF1R disruption were employed. In addition, small interfering RNA technology was used to specifically down-regulate INSR or IGF1R expression in T47D breast cancer cells. DNA affinity chromatography assays were conducted to address the specific binding of ERK1/2 and AKT to the promoter region. We demonstrate that both INSR and IGF1R exhibit a nuclear localization in breast cancer-derived cells. In addition, the insulin and IGF1 pathways have different effects on the subcellular distribution (and, particularly, the nuclear presence) of ERK1/2 and AKT molecules. Both cytoplasmic mediators are capable of binding and transactivating the promoter. In conclusion, our data are consistent with the notion that, in addition to their classical roles as targets for insulin-like molecules, both ERK1/2 and AKT are involved in transcriptional control of the gene. This previously unrecognized regulatory loop may provide mechanistic advantages to breast cancer cells. Given the potential role of INSR and IGF1R as therapeutic targets in oncology, it will be of clinical relevance to address the future use of nuclear receptors and their downstream cytoplasmic mediators as biomarkers for INSR/IGF1R targeted therapy.

Citing Articles

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade V, Bridgers J, Stubbins R Leukemia. 2025; .

PMID: 40000845 DOI: 10.1038/s41375-025-02537-2.


Investigation of the relationship between breast cancer and clinical symptoms of polycystic ovarian syndrome: a case-control study.

Hemati A, Amini L, Haghani S, Hashemi E BMC Womens Health. 2024; 24(1):586.

PMID: 39488687 PMC: 11531183. DOI: 10.1186/s12905-024-03421-4.


The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities.

Ennis C, Llevenes P, Qiu Y, Dries R, Denis G Front Endocrinol (Lausanne). 2022; 13:1044670.

PMID: 36531496 PMC: 9751481. DOI: 10.3389/fendo.2022.1044670.


A New Nonparametric Multivariate Control Scheme for Simultaneous Monitoring Changes in Location and Scale.

Yue J, Liu L Comput Math Methods Med. 2022; 2022:3385825.

PMID: 35832137 PMC: 9273427. DOI: 10.1155/2022/3385825.


Based on the Network Pharmacology to Investigate the Mechanism of Qingjie Fuzheng Granules against Colorectal Cancer.

Fang Y, Yang C, Lu Y, Wei L, Zhao J, Lu L Evid Based Complement Alternat Med. 2022; 2022:7242640.

PMID: 35280511 PMC: 8916896. DOI: 10.1155/2022/7242640.


References
1.
Ekyalongo R, Yee D . Revisiting the IGF-1R as a breast cancer target. NPJ Precis Oncol. 2017; 1. PMC: 5687252. DOI: 10.1038/s41698-017-0017-y. View

2.
Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J . SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal. 2010; 3(108):ra10. DOI: 10.1126/scisignal.2000628. View

3.
Scotlandi K, Picci P . Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008; 20(4):419-27. DOI: 10.1097/CCO.0b013e328302edab. View

4.
Girnita L, Worrall C, Takahashi S, Seregard S, Girnita A . Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci. 2013; 71(13):2403-27. PMC: 4055838. DOI: 10.1007/s00018-013-1514-y. View

5.
Rostoker R, Abelson S, Bitton-Worms K, Genkin I, Ben-Shmuel S, Dakwar M . Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer. 2015; 22(2):145-57. PMC: 4362669. DOI: 10.1530/ERC-14-0490. View